Owlstone Medical’s vision is to save 100,000 lives by realising the enormous promise of breath-based diagnostics through the development and application of Breath Biopsy®, a unique platform capable of both biomarker discovery and use in routine clinical testing. The Company’s Research Products and Services are now being deployed at over 100 sites around the world with large pharmaceutical companies including AstraZeneca, Actelion (a J&J company), and GlaxoSmithKline, and leading academic institutions.
Zyme has worked with Owlstone Medical and its parent company, Owlstone Inc., since 2014. Zyme initially supported Owlstone with the development of a strategic PR and communications plan to establish Owlstone Medical as a standalone company and raise awareness with new investors, customers and potential partners in industry and academia. Since then, Zyme has continued to support Owlstone to evidence breath analysis as a proven diagnostic test and position the Company as the leader in the field.
With Owlstone Medical’s continued success and development, the ongoing objectives have prioritised positioning the Company as an established and growing multinational organisation with proven technology and international investors, and profiling its dual strategy for biomarker discovery – endogenous metabolites and exogenous ‘EVOC’ probes.
Most recently, the launch of OMED Health, a patient-centric platform, expanded Owlstone Medical’s focus to include digestive disease and gut health, maximising patient benefit of the Company’s breath testing technology.
- Elevated coverage in national and international press, with pieces in The New York Times, The Financial Times, The Sunday Times and The Economist, as well as across top life science and health science publications, including thought-leadership interviews with CEO, Billy Boyle, targeted press releases, awards, technical articles, and media briefing meetings.
- Facilitated ongoing messaging development through regular workshops with the senior leadership team, defining Owlstone’s proposition and key messages that resonate with each target audience, and ensuring consistent messaging across all communications
- Supported communications announcing the launch and completion of significant clinical trials, including with CRUK, to generate outstanding level of interest from key audiences.
- Provided strategic communications advice to align business and communications objectives, including recommendations for the launch of a new website and working alongside Owlstone’s marketing team and web design agency.
- Coordination with B2C marketing agency to support launch of OMED Health at-home solution for patients and healthcare professionals, including developing communications strategy and messaging that resonates across technical, consumer, and investor audiences.
- Built and managed social media profiles to maximise engagement with target audiences and drive traffic to the website.
Zyme has provided us with strategic guidance and a very proactive approach in developing our PR and communications programme. Zyme’s industry knowledge and network of media contacts has created opportunities for us to build our profile and establish breath as a new diagnostic modality. We have been very impressed by the breadth and quality of media coverage achieved on a regular basis, in key trade publications and global business press.
Billy Boyle, Co-Founder and CEO, Owlstone Medical